pyrroles has been researched along with adamantane in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Choe, E; Ferrara, J; Flint, L; Franklin, E; Grivas, T; Hyman, A; Lippton, H | 1 |
| Khan, SA; Meisheri, KD; Ohrnberger, CE | 1 |
| Cipkus-Dubray, LA; Humphrey, SJ; Jones, AW; Khan, SA; Meisheri, KD; Smith, MP | 1 |
| Gill, I; Patel, R | 1 |
| Nuermberger, EL; Spigelman, MK; Yew, WW | 1 |
| Crans, DC; Crick, DC; Fontes, FL; Franzblau, SG; Grzegorzewicz, AE; Jackson, M; Jones, V; Lee, RE; Li, W; North, EJ; Upadhyay, A; Wang, Y | 1 |
| Azumaya, I; Itoh, T; Minamoto, C; Ohara, K; Tominaga, M; Yamaguchi, K; Yoneta, T | 1 |
| Dohi, T; Kita, Y; Koseki, D; Morimoto, K; Ogawa, R; Takahashi, Y | 1 |
| Bhakta, S; Brown, AK; Castagnolo, D; Dasugari, S; Evangelopoulos, D; Maitra, A; Manetti, F; McHugh, TD; Mortazavi, PN; Petricci, E; Scalacci, N; Twist, A | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Bando, T; Guo, C; Hashiya, K; Sugiyama, H; Wei, Y; Yu, Z | 1 |
| Chen, J; Huang, L; Li, J; Li, X; Ren, T; Yang, X; Zhong, S | 1 |
| Westhovens, R | 1 |
| Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Morinobu, A | 1 |
| Karkara, BB; Kumar, A; Panda, G | 1 |
| Kim, JW; Kim, SY | 1 |
| Audebert, P; Borsali, R; Brachi, M; Buzzetti, PHM; Cosnier, S; Gorgy, K; le Goff, A; Li, H; Shan, D | 1 |
9 review(s) available for pyrroles and adamantane
| Article | Year |
|---|---|
Current development and future prospects in chemotherapy of tuberculosis.
Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary | 2010 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Topics: Adamantane; Animals; Antitubercular Agents; DNA Gyrase; Drug Development; Enzyme Inhibitors; Humans; Isonicotinic Acids; Mycobacterium tuberculosis; Oxazolidinones; Piperidines; Pyrroles; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant; Uridine | 2021 |
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
12 other study(ies) available for pyrroles and adamantane
| Article | Year |
|---|---|
Femoral vasodilation to cromakalim is blocked by U37883A, a non-sulphonylurea that selectively inhibits KATP channels.
Topics: Adamantane; Analysis of Variance; Animals; Benzopyrans; Cromakalim; Dogs; Drug Interactions; Femur; Injections, Intravenous; Isoproterenol; Morpholines; Nitroglycerin; Potassium Channels; Pyrroles; Regional Blood Flow; Serotonin; Serotonin Receptor Agonists; Vasodilation; Vasodilator Agents | 1995 |
Synergistic effects of glyburide and U-37883A, two structurally different vascular ATP-sensitive potassium channel antagonists.
Topics: Adamantane; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Drug Synergism; Gallopamil; Glyburide; In Vitro Techniques; Ion Channel Gating; Male; Mesenteric Arteries; Minoxidil; Morpholines; Potassium Channels; Pyrroles; Rabbits; Vasodilation | 1993 |
4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexylhydrochloride (U-37883A): pharmacological characterization of a novel antagonist of vascular ATP-sensitive K+ channel openers.
Topics: Adamantane; Adenosine Triphosphate; Animals; Benzopyrans; Blood Pressure; Cats; Cromakalim; Dogs; Female; In Vitro Techniques; Male; Mesenteric Arteries; Minoxidil; Morpholines; Potassium; Potassium Channels; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Vasodilation | 1993 |
Biocatalytic ammonolysis of (5S)-4,5-dihydro-1H-pyrrole-1,5-dicarboxylic acid, 1-(1,1-dimethylethyl)-5-ethyl ester: preparation of an intermediate to the dipeptidyl peptidase IV inhibitor Saxagliptin.
Topics: Adamantane; Ammonia; Asbestos; Biotechnology; Calcium Chloride; Carbamates; Carbon Dioxide; Catalysis; Dicarboxylic Acids; Dipeptides; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Esters; Ethane; Ethanol; Fungal Proteins; Lipase; Molecular Structure; Nitrogen; Pyrroles; Sodium Hydroxide; Stereoisomerism | 2006 |
Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
Topics: Adamantane; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carrier Proteins; Cell Membrane; Cord Factors; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Mycolic Acids; Phenylurea Compounds; Piperazines; Proton Ionophores; Pyrroles; Tuberculosis, Multidrug-Resistant; Valinomycin; Vitamin K 2 | 2014 |
Self-assembly of a tetrapodal adamantane with carbazole branches into hollow spherical aggregates in organic media.
Topics: Adamantane; Carbazoles; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Molecular Structure; Polymers; Pyrroles; Solvents | 2014 |
Clean Synthesis of N-Pyrrolyl Azoles by Metal-Free Oxidative Cross-Coupling Using Recyclable Hypervalent Iodine Reagent.
Topics: Adamantane; Azoles; Green Chemistry Technology; Indicators and Reagents; Iodine; Oxidation-Reduction; Pyrroles | 2015 |
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
Topics: Adamantane; Antitubercular Agents; Carrier Proteins; Cell Line; Cell Survival; Computational Biology; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Mycobacterium tuberculosis; Pharmaceutical Preparations; Piperazines; Pyrroles; Structure-Activity Relationship | 2016 |
Pip-HoGu: An Artificial Assembly with Cooperative DNA Recognition Capable of Mimicking Transcription Factor Pairs.
Topics: Adamantane; Cell Line, Tumor; Cyclodextrins; DNA; Humans; Imidazoles; Molecular Structure; Nylons; Pyrroles; Transcription Factors | 2018 |
Assembling of stimuli-responsive tumor targeting polypyrrole nanotubes drug carrier system for controlled release.
Topics: Adamantane; Antineoplastic Agents; beta-Cyclodextrins; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Liberation; Folic Acid; HEK293 Cells; Humans; Microscopy, Electron, Scanning; Nanotubes; Polyethylene Glycols; Polymers; Pyrroles; Spectroscopy, Fourier Transform Infrared | 2018 |
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane | 2019 |
Trialkoxyheptazine-Based Glyconanoparticles for Fluorescence in Aqueous Solutions and on Surfaces via Controlled Binding in Space.
Topics: Adamantane; Cyclodextrins; Fluorescence; Pyrroles; Water | 2022 |